Transarterial chemoembolization for management of hemoptysis: initial experience in advanced primary lung cancer patients
| Autor: | Chigusa Shimono, Akihiko Seki |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Hemoptysis Lung Neoplasms medicine.medical_treatment 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Refractory medicine Humans Radiology Nuclear Medicine and imaging Embolization Chemoembolization Therapeutic Lung cancer Aged Cisplatin Aged 80 and over business.industry Drug infusion Middle Aged medicine.disease Radiation therapy Treatment Outcome 030220 oncology & carcinogenesis Hemostasis Adenocarcinoma Gelatin Radiology business medicine.drug |
| Zdroj: | Japanese journal of radiology. 35(9) |
| ISSN: | 1867-108X |
| Popis: | To evaluate the hemostatic effects of transarterial infusion chemotherapy in addition to embolization (chemoembolization) for advanced primary lung cancer with tumor-related hemoptysis. Ten consecutive patients with stage IIIB/IV or recurrent primary lung cancer (squamous cell carcinoma in six, adenocarcinoma in four) who underwent chemoembolization for control of hemoptysis were enrolled. At enrollment, five patients were considered refractory and five had contraindications to standard therapies. The amount of hemoptysis was massive in two patients, moderate in seven, and slight in one. Transarterial infusion chemotherapy via feeding arteries using cisplatin (25 mg/m2) and 5-fluorouracil (300 mg/m2) was repeated every 3–4 weeks for three cycles. HepaSphere (100–150 µm) or gelatin sponge particles were selected as embolic materials depending on the presence of pulmonary shunts and were added for embolization just after drug infusion. Hemoptysis improved in all patients (resolution in nine, significant decrease in one). The median hemostasis time was 11.9 months (range 2.7–25.9 months). The target pulmonary lesions shrank in seven patients, and pulmonary atelectasis disappeared in three of five patients. Chemoembolization may be a palliative option with favorable hemostasis time for advanced primary lung cancer with hemoptysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink